Robert Pelzer Net Worth

Robert Pelzer biography

Robert E. Pelzer serves as Independent Chairman of the Board of the Company. Mr. Pelzer From September 2008 to March 2013, Mr. Pelzer served as the President of Novartis Corporation, a pharmaceutical company. From 2002 to 2008, Mr. Pelzer served as General Counsel at Novartis Pharma AG. Prior to 2002, Mr. Pelzer held various positions at DuPont, including serving as General Counsel and Senior Vice President at DuPont Pharmaceuticals from 1998 to 2001. Mr. Pelzer currently serves on the Board of Directors of Qu Biologics and previously served on the Board of Directors of Aquinox Pharmaceuticals and Idenix Pharmaceuticals, Inc. Mr. Pelzer holds a BCom and an LL.B. from the University of Alberta. Our Board of Directors believes that Mr. Pelzer should serve as a director based upon his extensive experience in the healthcare industry.

What is the salary of Robert Pelzer?

As the Independent Chairman of the Board of Sierra Oncology Inc, the total compensation of Robert Pelzer at Sierra Oncology Inc is $80,411. There are 6 executives at Sierra Oncology Inc getting paid more, with Barbara Klencke having the highest compensation of $971,397.

How old is Robert Pelzer?

Robert Pelzer is 66, he's been the Independent Chairman of the Board of Sierra Oncology Inc since 2019. There are no older and 16 younger executives at Sierra Oncology Inc.

What's Robert Pelzer's mailing address?

Robert's mailing address filed with the SEC is C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DR., SUITE 110, SAN MATEO, CA, 94404.

Insiders trading at Sierra Oncology Inc

Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth a James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.

What does Sierra Oncology Inc do?

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Sierra Oncology Inc executives and stock owners

Sierra Oncology Inc executives and other stock owners filed with the SEC include:

• Barbara Klencke,
  Chief Development Officer
• Mark Kowalski,
  Chief Medical Officer
• Sukhi Jagpal,
  Chief Financial Officer
• Dr. Stephen George Dilly M.B.B.S, Ph.D.,
  Pres, CEO & Director
• Dr. Barbara J. Klencke M.D.,
  Chief Medical Officer
• Dr. Mark M. Kowalski M.D., Ph.D.,
  Chief of Research & Early Devel.
• Robert Pelzer,
  Independent Chairman of the Board
• James Smith,
  Vice President Corporate Affairs
• Andrew Sinclair,
  Independent Director
• Josh Richardson,
  Independent Director
• Jeffrey Cooper,
  Independent Director
• Mona Ashiya,
  Independent Director
• Andrew Allen,
  Independent Director
• Gaurav Aggarwal,
  Independent Director
• Craig Collard,
  Director
• William Turner,
  Chief Regulatory and Technical Operations Officer
• Kevin Norrett,
  Chief Business Officer
• Christina Thomson,
  General Counsel
• Stephen Dilly,
  President, Chief Executive Officer, Director
• Kevin Norrett M.B.A., M.S.,
  Chief Bus. Officer
• William D. Turner,
  Chief Regulatory & Technical Operations Officer
• Christina Thomson J.D., M.S.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Sukhi Jagpal CA, CPA, CBV, MBA,
  Chief Financial Officer
• Daniel Estes,
  Director
• James N Topper,
  Director
• Nicholas Glover,
  CEO and President
• Nicole Onetto,
  Director
• Tran Nguyen,
  Director
• Donald R Parfet,
  Director
• Angie You,
  Chief Bus. & Strat. Officer
• Capital Partners Iii, Llc L...,
  
• Christian Hassig,
  Chief Scientific Officer
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llcorbimed Capital...,
  
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llc Orbi Med Capit...,
  
• Georgia Erbez,
  Director
• Christy J. Oliger,
  Director
• Llp Abingworth,
  10% owner
• Mary Christina Thomson,
  General Counsel
• Advisors Llc Orbi Med Capit...,